MX2013010910A - Peptidos neuroprotectores. - Google Patents
Peptidos neuroprotectores.Info
- Publication number
- MX2013010910A MX2013010910A MX2013010910A MX2013010910A MX2013010910A MX 2013010910 A MX2013010910 A MX 2013010910A MX 2013010910 A MX2013010910 A MX 2013010910A MX 2013010910 A MX2013010910 A MX 2013010910A MX 2013010910 A MX2013010910 A MX 2013010910A
- Authority
- MX
- Mexico
- Prior art keywords
- acid sequence
- amino acid
- amino acids
- cd44v10
- neuroprotective peptides
- Prior art date
Links
- 230000000324 neuroprotective effect Effects 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 150000001413 amino acids Chemical class 0.000 abstract 2
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70585—CD44
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Psychology (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161466966P | 2011-03-24 | 2011-03-24 | |
| PCT/IL2012/050104 WO2012127475A1 (en) | 2011-03-24 | 2012-03-22 | Neuroprotective peptides |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2013010910A true MX2013010910A (es) | 2014-03-27 |
Family
ID=45999925
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2013010910A MX2013010910A (es) | 2011-03-24 | 2012-03-22 | Peptidos neuroprotectores. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20140045764A1 (OSRAM) |
| EP (1) | EP2688582B1 (OSRAM) |
| JP (1) | JP5960793B2 (OSRAM) |
| KR (1) | KR20140036164A (OSRAM) |
| CN (1) | CN103648517B (OSRAM) |
| AU (1) | AU2012232642B2 (OSRAM) |
| BR (1) | BR112013024323A2 (OSRAM) |
| CA (1) | CA2830792A1 (OSRAM) |
| EA (1) | EA201391387A1 (OSRAM) |
| MX (1) | MX2013010910A (OSRAM) |
| SG (1) | SG193418A1 (OSRAM) |
| WO (1) | WO2012127475A1 (OSRAM) |
| ZA (1) | ZA201307169B (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201220899D0 (en) * | 2012-11-21 | 2013-01-02 | Kit Karlsrusher Inst Fuer Technologie Und Inst Fuer Toxikologie Und Genetik And Amcure Gmbh | CD44v6-derived pegylated peptides |
| WO2017131468A1 (ko) * | 2016-01-27 | 2017-08-03 | 경상대학교산학협력단 | 아디포넥틴 수용체 활성화 신규 펩티드를 유효성분으로 포함하는 신경질환의 예방, 개선 또는 치료용 조성물 |
| US10981956B2 (en) | 2016-03-31 | 2021-04-20 | Senju Pharmaceutical Co., Ltd. | Neuroprotective peptide |
| WO2017170926A1 (ja) * | 2016-03-31 | 2017-10-05 | 千寿製薬株式会社 | 神経保護ペプチド |
| US12304932B2 (en) | 2017-11-14 | 2025-05-20 | Senju Pharmaceutical Co., Ltd. | PACAP stabilized peptide |
| AU2019374743B2 (en) | 2018-11-08 | 2022-03-03 | Neovasc Tiara Inc. | Ventricular deployment of a transcatheter mitral valve prosthesis |
| ES3045907T3 (en) | 2019-05-14 | 2025-12-01 | Senju Pharma Co | Composition for preventing or treating neurotrophic keratitis which contains stabilized pacap peptide |
| PL3974027T3 (pl) | 2019-05-14 | 2025-02-24 | Senju Pharmaceutical Co., Ltd. | Stabilizowany peptyd pacap |
| CN112569351B (zh) * | 2020-12-16 | 2021-10-15 | 南通大学 | Cd44抗体在制备治疗帕金森疾病的药物中的应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| WO1995000658A1 (en) * | 1993-06-18 | 1995-01-05 | Sirpa Jalkanen | COMPOSITIONS AND DIAGNOSTIC METHODS USING MONOCLONAL ANTIBODIES AGAINST CD44v6 |
| CA2179391A1 (en) * | 1994-01-18 | 1995-07-20 | Edgar Haber | Cd44 expression in smooth muscle cells |
| DE19653607A1 (de) * | 1996-12-20 | 1998-06-25 | Boehringer Ingelheim Int | Verfahren zur Diagnose und Therapie von Hodgkin-Lymphomen |
| US6559287B1 (en) * | 1998-01-24 | 2003-05-06 | Bristol-Myers Squibb Co. | Artificial proteoglycans |
| EP1647556B1 (en) * | 2004-10-14 | 2010-05-19 | Karlsruher Institut für Technologie | Peptidic compounds and derivatives thereof for the treatment of human diseases through inhibition of signaling via growth factors |
| KR20100044793A (ko) * | 2007-07-10 | 2010-04-30 | 뉴림 파머슈티칼스 (1991) 리미티드 | 신경퇴행성 질환에서 ｃｄ44 접목 변이체들 |
| EP2266593A1 (en) * | 2009-06-24 | 2010-12-29 | Karlsruher Institut für Technologie | Use of CD44v6 in the treatment of ophthalmic diseases |
-
2012
- 2012-03-22 KR KR1020137027914A patent/KR20140036164A/ko not_active Withdrawn
- 2012-03-22 EA EA201391387A patent/EA201391387A1/ru unknown
- 2012-03-22 WO PCT/IL2012/050104 patent/WO2012127475A1/en not_active Ceased
- 2012-03-22 US US14/007,010 patent/US20140045764A1/en not_active Abandoned
- 2012-03-22 CA CA2830792A patent/CA2830792A1/en not_active Abandoned
- 2012-03-22 EP EP12716661.9A patent/EP2688582B1/en active Active
- 2012-03-22 BR BR112013024323A patent/BR112013024323A2/pt not_active Application Discontinuation
- 2012-03-22 SG SG2013068499A patent/SG193418A1/en unknown
- 2012-03-22 AU AU2012232642A patent/AU2012232642B2/en active Active
- 2012-03-22 JP JP2014500540A patent/JP5960793B2/ja active Active
- 2012-03-22 MX MX2013010910A patent/MX2013010910A/es not_active Application Discontinuation
- 2012-03-22 CN CN201280014793.1A patent/CN103648517B/zh active Active
-
2013
- 2013-09-18 ZA ZA2013/07169A patent/ZA201307169B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP5960793B2 (ja) | 2016-08-02 |
| US20140045764A1 (en) | 2014-02-13 |
| CA2830792A1 (en) | 2012-09-27 |
| BR112013024323A2 (pt) | 2017-06-13 |
| SG193418A1 (en) | 2013-10-30 |
| EA201391387A1 (ru) | 2014-01-30 |
| AU2012232642A1 (en) | 2013-10-17 |
| JP2014510101A (ja) | 2014-04-24 |
| ZA201307169B (en) | 2014-05-28 |
| CN103648517A (zh) | 2014-03-19 |
| EP2688582A1 (en) | 2014-01-29 |
| EP2688582B1 (en) | 2017-02-15 |
| AU2012232642B2 (en) | 2016-12-08 |
| WO2012127475A1 (en) | 2012-09-27 |
| KR20140036164A (ko) | 2014-03-25 |
| CN103648517B (zh) | 2016-04-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2013010910A (es) | Peptidos neuroprotectores. | |
| AU2018253546A1 (en) | Aromatic-cationic peptides and methods for using same | |
| EA202090053A3 (ru) | Способы и композиции для лечения неэффективного эритропоэза | |
| IN2014KN01713A (OSRAM) | ||
| IN2014KN01714A (OSRAM) | ||
| IN2014KN01716A (OSRAM) | ||
| IN2014KN01715A (OSRAM) | ||
| MX358224B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de higado. | |
| WO2017009843A3 (en) | Compositions, articles of manufacture and methods for treating cancer | |
| MX357965B (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer de vesicula biliar. | |
| NZ601868A (en) | Tissue protective peptides and peptide analogs for preventing and treating diseases and disorders associated with tissue damage | |
| MX2014001372A (es) | Composicion farmaceutica para el tratamiento y/o prevencion de cancer pancreatico. | |
| MX340014B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340015B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| CA2889275C (en) | Novel method for treating cardiac infarction using hmgb1 fragment | |
| IN2014CN04498A (OSRAM) | ||
| MX360030B (es) | Metodos para tratar el trastorno bipolar. | |
| NZ602845A (en) | Inhibiting peptides derived from trem-like transcript 1 (tlt-1) and uses thereof | |
| MX392388B (es) | Metodo cosmetico para el tratamiento o reduccion de paniculopatia edemato-fibroesclerotica (pefe) | |
| WO2012177653A3 (en) | Targeting the neuromuscular junction for treatment | |
| WO2014082042A3 (en) | Peptides that stimulate subcutaneous adipogenesis | |
| WO2013173827A3 (en) | Methods and compositions for inhibiting diseases of the central nervous system | |
| WO2012153337A3 (en) | Anti-microbial peptides and uses of same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |